246 related articles for article (PubMed ID: 29516187)
21. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer.
Başpınar Y; Erel-Akbaba G; Kotmakçı M; Akbaba H
Int J Pharm; 2019 Jul; 566():149-156. PubMed ID: 31129344
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
[TBL] [Abstract][Full Text] [Related]
23. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma.
Kumar MR; Aithal BK; Udupa N; Reddy MS; Raakesh V; Murthy RS; Raju DP; Rao BS
Drug Deliv; 2011; 18(7):511-22. PubMed ID: 21793763
[TBL] [Abstract][Full Text] [Related]
24. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
25. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
26. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
28. YM155 induces EGFR suppression in pancreatic cancer cells.
Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
[TBL] [Abstract][Full Text] [Related]
29. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
30. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
31. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
33. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
Brown BS; Patanam T; Mobli K; Celia C; Zage PE; Bean AJ; Tasciotti E
Cancer Biol Ther; 2014 Jul; 15(7):851-61. PubMed ID: 24755919
[TBL] [Abstract][Full Text] [Related]
34. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
35. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
37. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
38. Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Liang B; Shahbaz M; Wang Y; Gao H; Fang R; Niu Z; Liu S; Wang B; Sun Q; Niu W; Liu E; Wang J; Niu J
Clin Cancer Res; 2015 Mar; 21(5):1183-95. PubMed ID: 25549721
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
40. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
